-

11:39:03 PM

AFMD Stock News

AFMD - Affimed N.V.

05/26/22 5:05 PM

Nasdaq : AFMD

clinical trial

Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Design and rationale of the phase 1/2a open label, multicenter study of the AFM24 monotherapy in patients with advanced EGFR-expressing solid tumors Design and rationale of the phase 1/2a study of AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors Design

RHEA-AI

neutral

05/26/22 6:30 AM

Nasdaq : AFMD

conferences

Affimed to Present at the 2022 Jefferies Healthcare Conference

Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will

RHEA-AI

neutral

05/24/22 6:30 AM

Nasdaq : AFMD

conferencesearnings

Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022

Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2022 results and

RHEA-AI

neutral

05/24/22 6:30 AM

Nasdaq : AFMD

Affimed Announces Annual General Meeting of Shareholders

Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2022 Annual General Meeting of Shareholders

RHEA-AI

neutral

05/16/22 8:00 AM

Nasdaq : AFMD

Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity

Correlative science data from AFM24-101 clinical study support the rationale to develop AFM24 as monotherapy and in combination therapies First preclinical data set on the combination of AFM28 with natural killer cells, both in co-administration or pre-complexed, demonstrates cytotoxic activity

RHEA-AI

neutral

05/12/22 10:31 AM

Nasdaq : AFMD

conferencesclinical trial

Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

The novel bispecific innate cell engager AFM28 stimulates NK cells to destroy CD123-positive tumor cells via antibody-dependent cellular cytotoxicity. AFM28 induces effective lysis of hematological tumor cells even at low-levels of CD123 expression; leukemic cells in patient bone marrow are

RHEA-AI

neutral

05/06/22 4:02 PM

Nasdaq : AFMD

Affimed Provides Update on ASCO AFM13-104 Oral Presentation

Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the American Society of Clinical Oncology (ASCO)

RHEA-AI

neutral

04/27/22 5:20 PM

Nasdaq : AFMD

CORRECTING and REPLACING -- Affimed N.V.

In a press release issued earlier today by Affimed N.V. (Nasdaq: AFMD), please note that the headline named an incorrect organization. It should have mentioned the annual meeting of the American Society of Clinical Oncology (ASCO), not the American Association for Cancer Research. The corrected

RHEA-AI

neutral

04/27/22 4:05 PM

Nasdaq : AFMD

Affimed Announces Clinical Update and Trial in Progress Posters at the Annual Meeting of the American Association for Cancer Research (ASCO)

A presentation on the phase 1/2 study evaluating cord blood-derived NK cells that are pre-complexed with the innate cell engager AFM13, in patients with CD30-positive lymphomas will be given in an oral abstract session. Three Trial in Progress posters will present background information and the

RHEA-AI

neutral

04/18/22 11:28 AM

Nasdaq : AFMD

offering

Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the closing of its previously announced public

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

AFMD Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.affimed.com
Security nameAffimed N.V.
Issue typecs
SectorManufacturing
Sic code2834
Employees158
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing

About Affimed N.V.

Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE®) molecules, which use patients' immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, New York, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients' lives.